Acquired Hemolytic Anemia Stocks List Ranked for

Symbol	Grade	Name	% Change
AKTX	C	Akari Therapeutics Plc	15.83
APLS	F	Apellis Pharmaceuticals, Inc.	2.64
IMVT	F	Immunovant, Inc.	0.44

Related Industries: Biotechnology

Symbol	Grade	Name	Weight
SBIO	B	ALPS Medical Breakthroughs ETF	2.93
XBI	B	SPDR S&P Biotech ETF	1.54
MNTL	D	Tema Neuroscience and Mental Health ETF	1.49
LABD	D	Direxion Daily S&P Biotech Bear 3X Shares	1.24
LABU	C	Direxion Daily S&P Biotech Bull 3X Shares	1.0

Compare ETFs

Date	Stock	Title
Oct 30	APLS	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Oct 29	IMVT	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Oct 29	APLS	1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Oct 28	APLS	Apellis, Sobi announced results from Phase 3 VALIANT study
Oct 26	APLS	Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Acquired Hemolytic Anemia: Acquired Hemolytic Anemia is a type of anemia that is caused by the destruction of red blood cells (RBCs) in the body. It can be caused by a variety of factors, including autoimmune disorders, infections, toxins, and certain medications. Symptoms of acquired hemolytic anemia include fatigue, pale skin, shortness of breath, and jaundice. Treatment typically involves medications to reduce the destruction of RBCs, as well as blood transfusions.